Rapid quantification of nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry

被引:53
作者
Ramakrishna, NS [1 ]
Vishwottam, KN [1 ]
Koteshwara, M [1 ]
Manoj, S [1 ]
Santosh, M [1 ]
Varma, DP [1 ]
机构
[1] Suven Life Sci Ltd, Biopharmaceut Res, Hyderabad 500034, Andhra Pradesh, India
关键词
nebivolol; reversed-phase chromatography; tandem mass spectrometry; multiple reaction monitoring; human plasma; pharmacokinetic study;
D O I
10.1016/j.jpba.2005.05.021
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A simple, sensitive and rapid liquid chromatographic/electrospray ionization tandem mass spectrometric method was developed and validated for the quantitation of nebivolol in human plasma. The method involved a simple single-step liquid-liquid extraction with diethyl ether/dichloromethane (70/30). The analyte was chromatographed on Waters symmetry (R) C-18 reversed-phase chromatographic column by isocratic elution with water: acetonitrile: formic acid (30:70:0.03, nu/nu) and analyzed by mass spectrometry in the multiple reaction monitoring mode. The precursor to product ion transitions of m/z 406.4-151.5 and m/z 409.1-228.1 were used to measure the analyte and the internal standard (I.S.), respectively. The chromatographic runtime was 2 min and the weighted (1/x(2)) calibration curves were linear over the range 50-10,000 pg/mL. The method was validated in terms of accuracy, precision, absolute recovery, freeze-thaw stability, bench-top stability and re-injection reproducibility. The limit of detection and lower limit of quantification in human plasma were 10 and 50 pg/mL, respectively. The within- and between-batch accuracy and precision were found to be well within acceptable limits (<10%). The analyte was stable after three freeze-thaw cycles (deviation <10%). The average absolute recoveries of nebivolol and tamsulosin, used as an internal standard, from spiked plasma samples were 73.4 +/- 3.7 and 72.1 +/- 2.0%, respectively. The assay method described here was applied to study the pharmacokinetics of nebivolol. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:1006 / 1013
页数:8
相关论文
共 23 条
[1]  
[Anonymous], 2001, GUID IND BIOAN METH
[2]   Nebivolol:: A third-generation β-blocker that augments vascular nitric oxide release endothelial β2-adrenergic receptor-mediated nitric oxide production [J].
Broeders, MAW ;
Doevendans, PA ;
Bekkers, BCAM ;
Bronsaer, R ;
van Gorsel, E ;
Heemskerk, JWM ;
Egbrink, MGAO ;
van Breda, E ;
Reneman, RS ;
van der Zee, R .
CIRCULATION, 2000, 102 (06) :677-684
[3]   Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects [J].
Cheymol, G ;
Woestenborghs, R ;
Snoeck, E ;
Ianucci, R ;
LeMoing, JP ;
Naditch, L ;
Levron, JC ;
Poirier, JM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 51 (06) :493-498
[4]   Nebivolol: a review [J].
Cockcroft, J .
EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (04) :893-899
[5]  
COCKCROFT JR, 1995, J PHARMACOL EXP THER, V274, P1067
[6]  
Jemal M, 2000, BIOMED CHROMATOGR, V14, P422, DOI 10.1002/1099-0801(200010)14:6<422::AID-BMC25>3.0.CO
[7]  
2-I
[8]  
KAMALI F, 1997, BR J CLIN PHARM, V51, P493
[9]  
LEE MS, 2002, LC MS APPL DRUG DEV
[10]   Nebivolol in the management of essential hypertension - A review [J].
McNeely, W ;
Goa, KL .
DRUGS, 1999, 57 (04) :633-651